Mylan launches Tecfidera generic amid Biogen battle

20-08-2020

Sarah Morgan

Mylan launches Tecfidera generic amid Biogen battle

ricochet64 / Shutterstock.com

Mylan launched its generic version of Biogen’s $4 billion-a-year multiple sclerosis drug Tecfidera (dimethyl fumarate) yesterday, August 19.


Mylan, Biogen, Tecfidera, patent, dimethyl fumarate, multiple sclerosis, MS, generics, FDA

LSIPR